Presented by VantagePoint AI: Lane Mendelsohn's patented AI just flagged three stocks with pattern formations that suggest major opportunity — setups that rarely align like this. Claim your free AI forecast before the crowd catches up →

Clinical data is running the tape this morning. One small-cap biotech is up more than 17% on a mid-stage readout that actually worked, while a European pharma giant is down double digits after a late-stage trial came back empty. That split is the entire economics of drug development compressed into one premarket session.

Elsewhere, the pattern is tailwinds versus broken models. An index addition and a sell-side upgrade are doing the lifting, while a downgrade rooted in structural decline and a cyberattack management tied directly to next year's targets are doing the damage.

Fellow Trader,

You spent four hours on charts last night.

And the move happened anyway. Without you.

Here's the uncomfortable part: more analysis isn't the answer. Better information is.

VantagePoint's patented AI identifies which sectors may be gaining strength before the crowd looks up from their candlesticks.

This free eBook shows you:

Why most traders are fighting the wrong battle

How to spot leading and losing sectors early

Why time frames matter more than anyone admits

Download "Predict the Leaders." Free.

Your charts will forgive you.

Lane Mendelsohn, President

Vantagepoint AI, LLC

1-800-732-5407 U.S. & Canada

Roivant Sciences (ROIV): +17%

A clean readout is the rarest thing in biotech, and Roivant just got one. Subsidiary Pulmovant reported Phase 2 results showing mosliciguat delivered a clinically meaningful and statistically significant reduction in pulmonary vascular resistance in patients with pulmonary hypertension tied to interstitial lung disease. For a company built on a portfolio of shots on goal, a hit this size resets the conversation about what the rest of the pipeline is worth.

Bloom Energy (BE): +7%

Index inclusion creates a buyer that has no choice, and Bloom is about to get one. The fuel-cell manufacturer joins the S&P 500 on Sept 21 after a year in which shares have climbed roughly 190% on AI data center power demand. The addition forces passive money into a name that momentum traders have already been crowding into all year.

Lockheed Martin (LMT): +1%

UBS moved Lockheed to Buy from Neutral, arguing the market is underappreciating the defense contractor's earnings growth potential. The price move is modest, but the framing is the point: the upgrade is a bet that investors have been valuing Lockheed on where it has been rather than where its earnings are heading.

Novartis (NVS): -13%

Phase 3 results showed del-desiran produced no significant improvement in patients with myotonic dystrophy type 1. A late-stage failure rarely touches the base business at a drugmaker this size, but it takes a pipeline asset off the board entirely. A double-digit drawdown in a large-cap pharma name is the market marking that slot down to nothing in a single session.

Peloton Interactive (PTON): -5%

Morgan Stanley cut Peloton to Underweight from Equal Weight, pointing to structural headwinds in fitness. That word choice carries more weight than the rating change itself, because structural is what analysts say when they no longer believe better execution fixes the problem.

Boston Scientific (BSX): -1%

The medical device maker said a recent cyberattack likely hit its sales and profit targets for 2026. Markets usually treat cyber incidents as one-time noise, but when management ties one directly to forward guidance, the read changes from an IT problem to an operating one.

Our AI system just flagged three stocks showing pattern formations that suggest major opportunity. These setups rarely align like this.

Our expert shows you the step-by-step process for turning thousands of tickers into a focused trading shortlist in mere minutes.

Claim Your Free AI Forecast.

To your success,

Lane Mendelsohn, President
Vantagepoint AI, LLC
1-800-732-5407 U.S. & Canada

Tyson Foods (TSN)

Retail chatter has been building around the protein complex since Friday, when President Trump signed executive orders designed to let ranchers process and sell beef directly, a move aimed squarely at the four packers that control roughly 85% of US cattle purchasing. Tyson is one of those four, and posters on r/stocks have spent the weekend arguing over whether this is a real margin threat or a policy with an implementation runway long enough to ignore.

The complication is timing. Tyson cut its fiscal 2026 outlook last week for the second time in a month, with the US cattle herd sitting near a 75-year low and its beef segment already the drag on the whole story. Traders seem to be watching whether Washington adds pressure to the one part of the business that could least afford it.

✌️That’s it for today.